Clinical trial

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

NCT05710666

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention trastuzumab deruxtecan (T-DXd) (IV) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2023-10-26

PhasePHASE2

Conditions

HER2-positive Breast Cancerunresolved

Interventions

trastuzumab deruxtecan (T-DXd) (IV)DRUG

Sponsors & collaborators

Cancer Trials Irelandlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05710666 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.